EXPERT CONSENSUS. ROLE OF COMBINATION LIPID-LOWERING THERAPY (SIMVASTATIN/EZETIMIBE 20/10 MG) IN THE CORRECTION OF LIPID METABOLISM DISTURBANCES IN PATIENTS WITH CHRONIC KIDNEY DISEASE

EXPERT CONSENSUS. ROLE OF COMBINATION LIPID-LOWERING THERAPY (SIMVASTATIN/EZETIMIBE 20/10 MG) IN THE CORRECTION OF LIPID METABOLISM DISTURBANCES IN PATIENTS WITH CHRONIC KIDNEY DISEASE

Expert Consensus. Role of combination lipid-lowering therapy (simvastatin/ezetimibe 20/10 mg) in the correction of lipid metabolism disturbances in patients with chronic kidney disease.

Bibliographic Details
Main Authors:	A. Catapano, E. V. Shlyakhto, A. I. Martynov, R. G. Oganov, V. V. Kukharchuk, M. V. Shestakova, A. S. Ametov, S. A. Boicov, M. G. Bubnova, S. V. Villevalde, A. S. Galyavich, Yu. A. Karpov, J. D. Kobalava, O. N. Koziolova
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2013-08-01
Series:	Кардиоваскулярная терапия и профилактика
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/217

Similar Items

Hypolipidemic and pleiotropic effects of a combination of simvastatin and ezetimibe in patients with different types of hyperlipidemia
by: A B Sumarokov, et al.
Published: (2014-12-01)

Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects
by: Kater Ana-Lucia A, et al.
Published: (2010-06-01)

Simultaneous Determination of Simvastatin and Ezetimibe in Tablets by HPLC
by: D. Anantha Kumar, et al.
Published: (2009-01-01)

Ezetimibe potential in cardiology practice
by: A. A. Lyakishev, et al.
Published: (1970-01-01)

Alirocoumab: new perspectives of lipid-lowering therapy
by: Zh D Kobalava, et al.
Published: (2017-12-01)

Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients
by: Osman Ahmed, et al.
Published: (2018-12-01)

Combined lipid lowering therapy, including ezetimibe, in the post-infarction period
by: V. E. Oleynikov, et al.
Published: (2024-05-01)

Role of Ezetimibe in Combination with Statins(Simvastatin and Atorvastatin) in Controlling Dyslipidemia
by: Falah H.Al-Malki, et al.
Published: (2017-03-01)

Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes
by: Hanson Mary E, et al.
Published: (2010-07-01)

Disorders of lipid metabolism. Clinical Guidelines 2023
by: M. V. Ezhov, et al.
Published: (2023-06-01)

The lipid-lowering effect of ezetimibe in pure vegetarians
by: Jacob J. Clarenbach, et al.
Published: (2006-12-01)

Ezetimibe/simvastatin (vytorin) in heart and renal protection: The SHARP trial
by: Alexander, W, et al.
Published: (2011)

Simultaneous HPTLC Estimation of Simvastatin and Ezetimibe in Tablet Dosage Form
by: Bhupendra Shrestha, et al.
Published: (2010-01-01)

Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
by: S. N. Tereshchenko, et al.
Published: (2020-06-01)

VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate
by: Michel Farnier, et al.
Published: (2008-12-01)

Microemulsion Liquid Chromatographic Method for Simultaneous Determination of Simvastatin and Ezetimibe in Their Combined Dosage Forms
by: Mohammed E. A. Hammouda, et al.
Published: (2013-01-01)

Simultaneous inhibition of cholesterol absorption and synthesis in combined therapy with ezetimibe and simvastatin
by: D. M. Aronov
Published: (2005-08-01)

A report of successful management with simvastatin plus ezetimibe in alopecia areata
by: Javier Arellano, et al.
Published: (2020-11-01)

Simvastatin and Ezetimibe-Loaded Nanofibers Administered Locally to Augment Bone Healing
by: Shayan Amiri, et al.
Published: (2021-01-01)

Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men
by: Thomas Sudhop, et al.
Published: (2009-10-01)

Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia
by: André J Tremblay, et al.
Published: (2009-07-01)

Physical Stability and Viscoelastic Properties of Co-Amorphous Ezetimibe/Simvastatin System
by: Justyna Knapik-Kowalczuk, et al.
Published: (2019-03-01)

Interdisciplinary Expert Consensus: the place of original pitavastatin in primary and secondary prevention of cardiovascular diseases
by: M. G. Bubnova, et al.
Published: (2024-12-01)

Lipid-lowering treatment in the improvement of outcomes in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of PCSK9 inhibitors
by: G. R. Galstyan, et al.
Published: (2018-12-01)

ESCADRA: a randomised study. Part I: lipid-lowering effectiveness, safety and tolerability of ezetimibe, initial doses of original statins, and the combination of ezetimibe with initial doses of statins in patients with coronary heart disease and hyperlipidemia
by: M. Yu. Zubareva, et al.
Published: (2010-12-01)

Serum lipids and smoking status in coronary heart disease patients treated with simvastatin
by: L. R. Gazdanova, et al.
Published: (2010-04-01)

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
by: Farnier Michel, et al.
Published: (2011-11-01)

Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition.
by: Chunmiao Tie, et al.
Published: (2015-01-01)

The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatins⃞
by: Dawn E. Telford, et al.
Published: (2007-03-01)

Development and Validation of a Derivative Spectrophotometric Method for Simultaneous Determination of Simvastatin and Ezetimibe
by: Effat Souri, et al.
Published: (2010-01-01)

Preformulation Studies of Ezetimibe-Simvastatin Solid Dispersions in the Development of Fixed-Dose Combinations
by: Agata Górniak, et al.
Published: (2022-04-01)

The efficacy and safety of Simvastatin in the treatment of lipid abnormalities in diabetes mellitus
by: Ogbera A Okeoghene, et al.
Published: (2013-01-01)

Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial[S]
by: L. Jakulj, et al.
Published: (2010-04-01)

Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering.
by: Gounari, P, et al.
Published: (2010)

Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels.
by: Heiner K Berthold, et al.
Published: (2013-01-01)

Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)
by: Le Grazie Cristina, et al.
Published: (2010-05-01)

P2.05 ARTERIAL WALL FUNCTION IN PATIENTS WITH CORONARY HEART DISEASE AND DYSLIPIDEMIA, COMPARATIVE EFFICACY OF EZETIMIBE, STATINS AND THEIR COMBINATION
by: M.I. Tripoten, et al.
Published: (2010-12-01)

GENETIC PREDICTORS OF INTENSIVE LIPID-LOWERING THERAPY EFFICACY AND ITS ANTI-INFLAMMATORY EFFECTS IN VERY HIGH CARDIOVASCULAR RISK PATIENTS
by: M. A. Vorobyeva, et al.
Published: (2017-09-01)

Combined lipid-lowering therapy: choosing strategy and tactics
by: N. A. Koziolova
Published: (2010-08-01)

Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review
by: Naderi S, et al.
Published: (2012-12-01)